Proteome Analysis of Schizophrenia Patients Wernicke's Area Reveals an Energy Metabolism Dysregulation

Overview

Journal BMC Psychiatry

Publisher Biomed Central

Specialty Psychiatry

Date 2009 May 2

PMID 19405953

Citations 61

Authors

Daniel Martins-de-Souza

Wagner F Gattaz

Andrea Schmitt

Jose C Novello

Sergio Marangoni

Christoph W Turck

Emmanuel Dias-Neto

Affiliations

Soon will be listed here.

Abstract

Background: Schizophrenia is likely to be a consequence of DNA alterations that, together with environmental factors, will lead to protein expression differences and the ultimate establishment of the illness. The superior temporal gyrus is implicated in schizophrenia and executes functions such as the processing of speech, language skills and sound processing.

Methods: We performed an individual comparative proteome analysis using two-dimensional gel electrophoresis of 9 schizophrenia and 6 healthy control patients' left posterior superior temporal gyrus (Wernicke's area - BA22p) identifying by mass spectrometry several protein expression alterations that could be related to the disease.

Results: Our analysis revealed 11 downregulated and 14 upregulated proteins, most of them related to energy metabolism. Whereas many of the identified proteins have been previously implicated in schizophrenia, such as fructose-bisphosphate aldolase C, creatine kinase and neuron-specific enolase, new putative disease markers were also identified such as dihydrolipoyl dehydrogenase, tropomyosin 3, breast cancer metastasis-suppressor 1, heterogeneous nuclear ribonucleoproteins C1/C2 and phosphate carrier protein, mitochondrial precursor. Besides, the differential expression of peroxiredoxin 6 (PRDX6) and glial fibrillary acidic protein (GFAP) were confirmed by western blot in schizophrenia prefrontal cortex.

Conclusion: Our data supports a dysregulation of energy metabolism in schizophrenia as well as suggests new markers that may contribute to a better understanding of this complex disease.

Citing Articles

Enhancing Transcriptomic Insights into Neurological Disorders Through the Comparative Analysis of Shapley Values.

Castro-Martinez J, Vargas E, Diaz-Beltran L, Esteban F Curr Issues Mol Biol. 2024; 46(12):13583-13606.

PMID: 39727940 PMC: 11726880. DOI: 10.3390/cimb46120812.

Mass Spectrometry Imaging of Two Neocortical Areas Reveals the Histological Selectivity of Schizophrenia-Associated Lipid Alterations.

Osetrova M, Zavolskova M, Mazin P, Stekolschikova E, Vladimirov G, Efimova O Consort Psychiatr. 2024; 5(3):4-16.

PMID: 39526011 PMC: 11542914. DOI: 10.17816/CP15488.

Reactive Oxygen Species: Angels and Demons in the Life of a Neuron.

Biswas K, Alexander K, Francis M NeuroSci. 2024; 3(1):130-145.

PMID: 39484669 PMC: 11523706. DOI: 10.3390/neurosci3010011.

Genome-Wide Analysis of Genetic Diversity and Selection Signatures in Zaobei Beef Cattle.

Shi L, Zhang P, Liu Q, Liu C, Cheng L, Yu B Animals (Basel). 2024; 14(16).

PMID: 39199980 PMC: 11350888. DOI: 10.3390/ani14162447.

Focusing on mitochondria in the brain: from biology to therapeutics.

Song N, Mei S, Wang X, Hu G, Lu M Transl Neurodegener. 2024; 13(1):23.

PMID: 38632601 PMC: 11022390. DOI: 10.1186/s40035-024-00409-w.

References

George A, Holsinger R, McLean C, Tan S, Scott H, Cardamone T . Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Aging. 2005; 27(4):614-23. DOI: 10.1016/j.neurobiolaging.2005.03.014. View

Marini A, Spoletini I, Alex Rubino I, Ciuffa M, Bria P, Martinotti G . The language of schizophrenia: an analysis of micro and macrolinguistic abilities and their neuropsychological correlates. Schizophr Res. 2008; 105(1-3):144-55. DOI: 10.1016/j.schres.2008.07.011. View

Chen Q, Wang S, Thompson S, Hall E, Guttmann R . Identification and characterization of PEBP as a calpain substrate. J Neurochem. 2006; 99(4):1133-41. DOI: 10.1111/j.1471-4159.2006.04160.x. View

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

Sims C, Hofmann J, Anderson L, Shore A, Torrey E, Yolken R . Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry. 2000; 5(2):142-9. DOI: 10.1038/sj.mp.4000696. View

Garcia-Marti G, Aguilar E, Lull J, Marti-Bonmati L, Escarti M, Manjon J . Schizophrenia with auditory hallucinations: a voxel-based morphometry study. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 32(1):72-80. DOI: 10.1016/j.pnpbp.2007.07.014. View

Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K . Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006; 112(4):389-404. PMC: 3906709. DOI: 10.1007/s00401-006-0127-z. View

Hwu H, Liu C, Fann C, Ou-Yang W, Lee S . Linkage of schizophrenia with chromosome 1q loci in Taiwanese families. Mol Psychiatry. 2003; 8(4):445-52. DOI: 10.1038/sj.mp.4001235. View

Altar C, Jurata L, Charles V, Lemire A, Liu P, Bukhman Y . Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry. 2005; 58(2):85-96. DOI: 10.1016/j.biopsych.2005.03.031. View

10.

Arion D, Unger T, Lewis D, Levitt P, Mirnics K . Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry. 2007; 62(7):711-21. PMC: 2080683. DOI: 10.1016/j.biopsych.2006.12.021. View

11.

Chen J, Dodia C, Feinstein S, Jain M, Fisher A . 1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities. J Biol Chem. 2000; 275(37):28421-7. DOI: 10.1074/jbc.M005073200. View

12.

Marti-Bonmati L, Lull J, Garcia-Marti G, Aguilar E, Moratal-Perez D, Poyatos C . Chronic auditory hallucinations in schizophrenic patients: MR analysis of the coincidence between functional and morphologic abnormalities. Radiology. 2007; 244(2):549-56. DOI: 10.1148/radiol.2442060727. View

13.

Prabakaran S, Swatton J, Ryan M, Huffaker S, Huang J, Griffin J . Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004; 9(7):684-97, 643. DOI: 10.1038/sj.mp.4001511. View

14.

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

15.

Aston C, Jiang L, Sokolov B . Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res. 2004; 77(6):858-66. DOI: 10.1002/jnr.20208. View

16.

Ben-Shachar D, Bonne O, Chisin R, Klein E, Lester H, Aharon-Peretz J . Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: A FDG-PET study. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(4):807-13. DOI: 10.1016/j.pnpbp.2006.12.025. View

17.

Sivagnanasundaram S, Crossett B, Dedova I, Cordwell S, Matsumoto I . Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics Clin Appl. 2010; 1(10):1291-305. DOI: 10.1002/prca.200700230. View

18.

Gattaz W, Brunner J . Phospholipase A2 and the hypofrontality hypothesis of schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 1996; 55(1-2):109-13. DOI: 10.1016/s0952-3278(96)90154-4. View

19.

Szymanski H, Orfanos A, Narisawa K, Grosz R, Naylor E . Dihydropteridine reductase in schizophrenic patients. Psychiatry Res. 1985; 15(2):115-9. DOI: 10.1016/0165-1781(85)90047-2. View

20.

Mitelman S, Brickman A, Shihabuddin L, Newmark R, Hazlett E, Haznedar M . A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia. Neuroimage. 2007; 37(2):449-62. PMC: 1994089. DOI: 10.1016/j.neuroimage.2007.04.070. View